Skip to content

Abivax

  • About Us
    • Company
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
  • Science
    • Overview
    • Publications
  • Pipeline
    • Overview
    • Patients
    • Obefazimod for UC
    • Obefazimod for Crohn’s
    • Obefazimod for RA
    • ABX196 for HCC
  • News & Events
    • Press Releases
    • Press Coverage
    • Upcoming Events
  • Investors
    • Overview
    • Share Price
    • Investor Documents
    • General Meeting
  • Contact Us
  • ECCO 2022
Search
  • EN
  • FR
  • DE

News & Events

Press Coverage

  • 2022
  • 2021
  • 2020
  • 2019
  • 2018

PMLiVE

December 23, 2020

Abivax’s COVID-19 study declared Research National Priority by French government

Pharmafile

December 2, 2020

Triple action to effectively treat COVID-19 patients

European Biotechnology

December 1, 2020

Germany first EU country to launch COVID-19 therapy offensive?

Life Science Leader

November 30, 2020

Politics And The Pandemic — Where Are They Taking Biopharma?

BlastingNews

November 27, 2020

A therapy, such as ABX464, treats patients that are already infected to promote recovery

  • 1
  • 2
  • 3
  • …
  • 25
© 2023 All rights reserved by ABIVAX | Website created by Stratégie et communication digitale : JLL CONSEIL Privacy and Terms of Use
  • About Us
    • Company
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
  • Science
    • Overview
    • Publications
  • Pipeline
    • Obefazimod for UC
    • ABX196 for HCC
  • News & Events
    • Press Releases
    • Press Coverage
    • Upcoming Events
  • Investors
    • Share Profile
    • Share Price
    • Investor Documents
    • Analysts
    • General Meeting
Contact Us
  • Follow us on Twitter
  • Follow us on LinkedIn
  • Follow us on YouTube
  • Follow us on Google+